GlobeNewswire Inc.··SanofiSanofi's Tzield Wins FDA Approval to Treat Type 1 Diabetes in Younger Children
FDA approves $SANF's Tzield for children ages 1+ with stage 2 type 1 diabetes, expanding from prior 8+ restriction. First disease-modifying therapy for autoimmune condition.
SNYFDA approvalTzield